|
|
||||||||
1From the Department of Human Genetics, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; the 2McGill Ocular Genetics Center, McGill University Health Center, Montreal, Quebec, Canada; 3The Rotterdam Eye Hospital, Rotterdam, The Netherlands; the 4Institute of Human Genetics, German Science Foundation National Research Center for Environment and Health, Munich-Neuherberg, Germany; the 5Institute of Human Genetics, Technical University, Munich, Germany; the 6Department of Ophthalmology, State University of New York, New York; the 7Department of Ophthalmology, University of Illinois at Chicago, Chicago, Illinois; the 8Wilmer Eye Institute, John Hopkins University, Baltimore, Maryland; and the 9Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany.
| Abstract |
|---|
|
|
|---|
METHODS. The genomes of 93 consanguineous and nonconsanguineous patients with LCA and juvenile RP were analyzed for homozygous chromosomal regions by using SNP microarrays. This patient cohort was highly selected, as mutations in the known genes had been excluded with the LCA mutation chip, or a significant number of LCA genes had been excluded by comprehensive mutation analysis. Known LCA and juvenile RP genes residing in the identified homozygous regions were analyzed by sequencing. Detailed ophthalmic examinations were performed on the genotyped patients.
RESULTS. Ten homozygous mutations, including seven novel mutations, were identified in the CRB1, LRAT, RPE65, and TULP1 genes in 12 patients. Ten patients were from consanguineous marriages, but in two patients no consanguinity was reported. In 10 of the 12 patients, the causative mutation was present in the largest or second largest homozygous segment of the patients genome.
CONCLUSIONS. Homozygosity mapping using SNP microarrays identified mutations in a significant proportion (30%) of consanguineous patients with LCA and juvenile RP and in a small number (3%) of nonconsanguineous patients. Significant homozygous regions which did not map to known LCA or juvenile RP genes and may be instrumental in identifying novel disease genes were detected in 33 patients.
LCA exhibits significant clinical overlap with juvenile retinitis pigmentosa (RP). However, juvenile RP is considered milder and does not have congenital onset of visual impairment. Patients with juvenile RP usually experience night blindness within the first years of life, progress to a gradual loss of peripheral visual field, and eventually lose central vision. Mutations in CRB1, RDH12, and RPE65 can cause both juvenile RP and LCA.6 7 8 In addition, mutations in LRAT, MERTK, and TULP1 can cause juvenile RP, which in some cases may be clinically diagnosed as LCA.9 10 11
Patients affected by a recessive disease and born of a consanguineous union are likely to be homozygous for the disease-causing mutation and for polymorphisms in the region surrounding this mutation.12 Homozygosity mapping is therefore an effective method for locating the responsible gene in consanguineous families. In rare recessive diseases, as in LCA, the frequency of homozygous mutations can also be relatively high in patients with no apparent consanguinity, due to a (distant) common ancestor who cannot be traced in the available family history. The average size of a homozygous region inherited from a common ancestor living 10 generations ago measures 10 cM, a region that can readily be detected with high-density SNP microarrays.13
In this study we analyzed 93 patients (82 isolated patients and 4 small families, each with 2 to 4 affected sibs) with LCA and juvenile RP for homozygous regions using SNP microarrays. Thirty-three patients were born from consanguineous marriage or in populations with a high degree of consanguineous unions. For 60 patients, mainly from The Netherlands or Germany or of French Canadian descent, no consanguinity was reported. The patients included in the study represent a highly selected patient group, as known mutations in the known LCA genes had been excluded with the LCA mutation chip, or a significant number of LCA genes had been excluded by comprehensive mutation analysis. Known LCA and juvenile RP genes residing in homozygous regions were analyzed for mutations. This approach successfully identified homozygous mutations in 12 patients, including seven novel mutations in the CRB1, RPE65, and TULP1 genes. In most patients, the disease-causing mutation was present in the longest or second longest homozygous segment of the patients genome. Significant homozygous regions were detected in 33 consanguineous and nonconsanguineous patients, which did not map to known LCA or juvenile RP genes and may be instrumental to identify novel LCA genes. In fact, we have recently demonstrated the effectiveness of using these homozygous regions to identify new LCA genes. One family with four affected siblings was instrumental in identifying the CEP290 gene as an important cause of LCA, and two unrelated patients with LCA recently allowed us to identify the LCA5 gene.3 5
| Materials and Methods |
|---|
|
|
|---|
Thirty-three (35%) patients were born of a known consanguineous union, or originated from populations with a high rate of consanguineous marriages, such as those of the Middle East and Turkey. For 60 patients, no consanguinity was reported. Thirteen of the nonconsanguineous patients were from the French Canadian founder population of Quebec, 25 were from The Netherlands, 13 were from Germany, and 9 were from several other countries (Canada, United States, Italy, and Africa).
In 65 patient samples all known mutations in the known LCA genes were excluded with a genotyping microarray based on arrayed primer extension (APEX) technology (Asper Ophthalmics, Tartu, Estonia).14 15 This analysis, however, did not include the CEP290, LCA5, and RD3 genes, since these genes were not known at that time. In the remaining 27 patients, the involvement of at least four of the known LCA genes was excluded by single-strand conformation analysis (SSCA)16 or denaturing high-performance liquid chromatography (DHPLC). One consanguineous patient (31863) from Afghanistan had not been analyzed for mutations.
Informed consent was obtained from all participating individuals consistent with the tenets of the Declaration of Helsinki. The institutional review boards of the participating centers approved the study.
SNP Microarrays
DNA samples for SNP analysis were purified (QIAamp DNA Mini Kit; Qiagen, Valencia, CA). Most of the consanguineous patients were genotyped for 11,555 SNPs (GeneChip Human Mapping 10K Array; Affymetrix, Santa Clara, CA). French-Canadian patients were genotyped for 116,204 SNPs (GeneChip Human Mapping 100K Set, consisting of a 50K Hind and a 50K Xba array; Affymetrix). The remaining patients were genotyped for 262,000 SNPs (GeneChip Mapping 250K Nsp Array; Affymetrix). In addition, seven consanguineous patients who showed only a few or no homozygous regions with the 10K array were also analyzed at higher resolution with the 250K array. Array experiments were performed according to protocols provided by the manufacturer. Arrays were scanned and genotypes were called as described.17
The 10K SNP genotypes were analyzed for homozygous regions (ExcludeAR sheet; Excel, Microsoft, Redmond, WA).18 Chromosomal segments were accepted as homozygous if they contained
39 consecutive homozygous SNPs, since the likelihood that this would occur by chance is less than 1:100.18 These segments correspond to regions of (on average) 8 Mb and larger. The 100K and 250K SNP data were analyzed with the software package CNAG,19 and chromosomal segments were accepted to be homozygous if the loss-of-heterozygosity (LOH) score was
15. The LOH score is a measure for the likelihood of a stretch of SNPs to be homozygous based on the population SNP allele frequencies. An LOH score of
15 corresponds to regions of (on average) 4 Mb and larger.
Mutation Analysis
Known LCA and juvenile RP genes that resided in homozygous chromosomal segments were analyzed for mutations. Primers for amplification of the coding exons and splice junctions were described previously,6 or were designed with ExonPrimer (http://ihg.gsf.de/ihg/ExonPrimer.html/ provided in the public domain by the Institute for Human Genetics, Technical University of Munich, Germany) and Primer3.20 Primer sequences and PCR conditions can be requested from the authors. PCR products were purified with 96-well filter plates (Multiscreen HTS-PCR; Millipore, Bedford, MA) or by gel extraction (QiaQuick Gel Extraction Kit; Qiagen). Sequencing was performed with dye terminator chemistry (BigDye Terminator, ver. 3 on a 3730 or 3100 DNA Analyzer; Applied Biosystems, Inc., [ABI], Foster City, CA).
Ophthalmic Examinations
Ophthalmic files of all patients were studied extensively, and additional information was collected prospectively. The examination included best corrected visual acuity, refraction, ERG according to ISCEV (International Society for Clinical Electrophysiology of Vision) protocol, Goldmann perimetry using V4e and I4e targets, and fundus photography.
| Results |
|---|
|
|
|---|
As expected, the majority (28/33; 85%) of consanguineous patients carried significant homozygous regions in their genomes—on average, 6.5 homozygous regions with an average size of 18.7 Mb. These homozygous regions covered
4.1% of their genome. Approximately half (31/60; 52%) of the nonconsanguineous patients also carried significant homozygous regions, but a lower number (average, 2.8) and smaller (average, 8.8 Mb) than those in consanguineous patients. The homozygous regions covered
0.9% of the genomes of nonconsanguineous patients.
Identification of Mutations in Known LCA and Juvenile RP Genes
LCA and juvenile RP genes that resided in the identified homozygous regions in the remaining 59 patients were analyzed for mutations. We found that in 19 patients, one or more known LCA or juvenile RP gene(s) resided in the homozygous segments documented by the SNP array. The CRB1 gene resided in a homozygous segment in six patients, the TULP1 gene in four patients; the LRAT, MERTK, and RPE65 gene each in three patients; the RDH12 gene in two patients; and the AIPL1, CRX, and GUCY2D in one patient. No patients were homozygous for the chromosomal region containing the RPGRIP1 gene. The CEP290, LCA5, and RD3 genes were not analyzed, since they were identified during the course of the study.3 4 5
Sequence analysis of the known LCA genes in the respective patients identified 10 different homozygous mutations in 12 patients (Table 1) . Ten of the 12 patients in which homozygous mutations were identified were born of consanguineous unions. The average size of the homozygous region containing the disease-causing mutation was 24 Mb (range, 8–41 Mb). In 10 patients, the disease gene was present in the largest or second largest homozygous segment of the patients genome (Table 1) .
|
In patients 27241 and 27266 identical homozygous haplotypes surrounding the LRAT gene were identified by 100K SNP analysis, spanning 118 SNPs and 2.3 Mb of genomic DNA. In both patients, the same homozygous frameshift mutation (c.217_218delAT) was subsequently identified in the LRAT gene. The identical haplotypes suggest that this mutation represents a founder mutation in the French-Canadian population. We did not identify this mutation in the remaining French-Canadian patients. Of interest, the mutation was recently identified in a French LCA family,23 supporting the hypothesis that it may represent a founder mutation originating from France.
The three missense mutations in the CRB1 gene—p.Cys939Tyr, p.Cys948Tyr, and p.Cys1332Phe—all affect conserved cysteine residues in the EGF-like domains. These residues are involved in the formation of disulfide bridges, and the mutations are predicted to affect correct folding of the CRB1 protein.16 24 The splice site mutation c.718+2T>C in the TULP1 gene identified in two patients from Afghanistan (27208 and 31863) is expected to have a severe effect on splicing, since the invariable dinucleotide of the splice donor site of intron 7 is affected. The splice site mutation identified in patient 21978 severely affects the splice donor site of intron 10 of the TULP1 gene. The splice prediction score of this splice site dramatically decreases from 0.82 to 0.21 (NNSPLICE, ver. 0.925 ). The TULP1 missense mutation p.Leu461Val changes an amino acid residue that is completely conserved in TULP1 orthologues and TULP family members.26
Clinical information of patients with TULP1, CRB1, and LRAT mutations are summarized herein and in Tables 2 3 and 4 , respectively. No detailed clinical data were available for the two patients with RPE65 mutations (27279 and 27233).
|
|
|
|
After detecting the homozygous TULP1 mutation in patient 27208, we identified another Afghan patient (31863) with juvenile RP a few years later, who was not known to be related to the first patient. Clinical features (Table 2) in this patient were similar to the phenotype of patient 27208, and we therefore postulated a TULP1 mutation. Remarkably, mutation analysis of the TULP1 gene identified the same homozygous splice site mutation (c.718+2T>C) in this patient. Patient 31863 was healthy, except for a mild developmental delay. He started "headbobbing" at age 3 years. The pupils were briskly reactive, and there were no paradoxical pupils. We found vertical nystagmus and a small headturn.
Patient 27232 presented with nyctalopia, photoaversion, head bobbing, and side and central visual difficulties of 1 to 2 years duration at age 5 years. He was found to have a fine, small, horizontal, pendular nystagmus.
Patient 21978 presented with exotropia, nystagmus, and night blindness at the age of 2 years. At age 11 years, the visual acuity remained stable. The anterior segments then showed cortical lens opacities in both eyes. The optic discs were pink, and there was mild attenuation of the arterioles and some RPE mottling. There were distinct round atrophic lesions of the RPE with bone spicules in the periphery (Fig. 2A) . The ERG was nondetectable. His younger brother developed similar symptoms at age 5. Acuities were 20/30 OD and 20/70 OS, with +4.00 –3.00 x 180° refraction OU. Retinal aspects were similar to those of the affected sib (Fig. 2B) . His ERG also revealed a rod–cone pattern.
|
Patient 28606 presented at age 10 years, with a history of visual difficulties since birth. She had ureteral hypoplasia and had undergone surgery for it as an infant. On examination she also had amaurotic pupils, pendular nystagmus, and enophthalmos. There was no PPRPE. At age 14, her vision dropped to hand motion.
Patient 27235 has two siblings with retinal dystrophy and two cousins with retinal dystrophy and hearing loss. This patient was first seen at age 66 years and reported better eyesight during the day than at night. On examination, we found pendular horizontal nystagmus and no light perception vision. The eyes were microphthalmic.
In patient 21266, visual field testing was performed at age 8 and showed a concentric restriction of 10° to 20° on Goldmann perimetry (III4e)5. At that age, her visual acuity was counting fingers in both eyes.
Clinical Characteristics of Patients with LRAT Mutations
Patients 27241 and 27266 were French-Canadian patients who were not known to be related to each other. For as long as patient 27266 could remember, she had had visual difficulties with nyctalopia and did not experience photophobia. Her funduscopic findings at age 23 years (Table 4) also showed normal RPE and retinal appearance in the posterior pole, then a sharp demarcation to an area with significant retinal hypopigmentation outside the arcades and to the periphery (Fig. 3A) . Goldmann visual fields were 10° with the V4e target. Over the next 10 years, she maintained hand motion vision, but the VF declined to 5°, and she developed mild posterior subcapsular cataracts and a mild bulls eye maculopathy.
|
Localization of New LCA Genes
During the course of this study, we identified two new LCA genes: CEP290 and LCA5.3 5 The CEP290 gene was identified by homozygosity mapping in a consanguineous family that was included in this study and consisted of four affected sibs. The affected members of this family carried a homozygous intronic mutation (c.2991+1655A>G) that leads to the insertion of a cryptic exon in the CEP290 mRNA and a premature stop codon in the CEP290 protein. Of note, we identified this mutation homozygously or compound heterozygously in 21% of our LCA cohort.3
Comprehensive mutation analysis of the CEP290 gene was performed after the patients had been analyzed for homozygous regions with SNP microarrays. In the patients who were found to carry CEP290 mutations, we could therefore go back to see whether they carried homozygous regions in their genomes. In four patients who were homozygous for the c.2991+1655A>G mutation, the homozygous region surrounding the mutation was very small—between 1.1 and 2.1 Mb. These regions were not detected as significant homozygous regions in our 250K SNP analysis, suggesting that the cutoff score used in our analysis (LOH score
15, corresponding to regions of 4 Mb and larger) might be too stringent. The shared homozygous haplotypes in these patients spanned only 1.1 Mb, covering 106 identical SNP calls on the 250K SNP array (rs7959909–rs7399104). In 14 patients the c.2991+1655A>G mutation was found heterozygously, together with a heterozygous deleterious mutation on the second allele.3 In 10 of the 14 patients who were compound heterozygous for CEP290 mutations, no significant homozygous regions were detected in the patients genome.
Before this study, three chromosomal regions had been identified that contain unknown LCA genes: the LCA9 locus on 1p36,30 the LCA5 locus on 6q11-q16,31 and the LCA3 locus on 14q24.32 Two patients who were included in our study were homozygous at the LCA5 locus: one consanguineous patient (27240) from Morocco and one patient (28609) from the United States without reported consanguinity. The homozygous region in the Moroccan patient overlapping with the LCA5 locus spanned 40 Mb and was the second largest of the eight homozygous segments identified in this patient. In the nonconsanguineous patient, the homozygous segment was 9 Mb and was the second largest of the five homozygous segments in the patients genome. Analysis of a positional candidate gene within the overlapping homozygous regions recently allowed us to identify the LCA5 gene.5
Of interest, in one nonconsanguineous patient (28604) we identified a 6-Mb homozygous region that partially overlapped the LCA9 locus. She is from the Mohawk tribe, a founder population of the original Canadians. This homozygous region was the only one identified in the patients genome. Two patients exhibited large homozygous regions at the LCA3 locus: one consanguineous patient (28608) from Portugal and a patient from Turkey (20942). In the Portuguese patient, the homozygous region was 23 Mb and ranked fourth among nine homozygous segments. In the Turkish patient, the homozygous segment spanned 29 Mb and represented the second largest homozygous segment in the patients genome.
Ten consanguineous and 20 nonconsanguineous patients with significant homozygous segments in their genomes were not homozygous for any of the known LCA genes and loci. These patients on average carried 3.9 homozygous fragments in their genomes, ranging from 1 to 51 Mb (average, 13.7 Mb).
| Discussion |
|---|
|
|
|---|
4.1% of their genomes. This percentage is most likely an underestimate of the total homozygosity in the genomes since the criteria for accepting a region to be homozygous were quite strict, to avoid the inclusion of false-negative homozygous regions and to exclude regions that are homozygous due to haplotype blocks that are frequent in the population. Strikingly, half of the patients without reported consanguinity also carried significant homozygous regions in their genomes. As expected, these patients carried a lower number of homozygous regions that were also smaller than those in consanguineous patients. The homozygous regions covered
0.9% of their genomes. In patient 21266, the homozygous tracts covered more than 6% of the genome, but no consanguinity was reported. The occurrence of long homozygous tracts covering a substantial part of the genome in nonconsanguineous individuals has been reported.33 34 Possible explanations could be that the parents have a relatively recent (unknown) common ancestor or that there is substantial inbreeding in the patients population. Even if a patient is from an apparently outbred population, inbreeding can be high, because the patients ancestors all lived in the same village or geographical area. In 10 (30%) of 33 consanguineous patients, homozygosity mapping successfully identified a disease-causing mutation in one of the known LCA and juvenile RP genes, and in 2 (3%) of 60 patients with no reported consanguinity. The average size of the homozygous region containing the disease-causing mutation is 24 Mb, which is similar to the average size observed in a recent study.12 Of note, the disease fragment was the largest or second largest segment in 10 of 12 patients. In a recent study, the longest homozygous segment was the disease-associated segment in 17% of the consanguineous individuals,12 but the ranking of the other disease-associated segments was not shown. Although the number of patients analyzed in our study is small, our data suggest that the ranking of the disease segment can be helpful to predict which fragments may contain the disease gene.
The homozygous regions detected by SNP genotyping can also be used to identify new disease genes. During the course of this study we identified two new LCA genes: CEP290 and LCA5.3 5 In addition, we identified three patients who were homozygous at one of the two known LCA loci, which may be helpful in identifying the responsible genes. In 30 patients, we identified significant homozygous regions and excluded all known LCA and juvenile RP genes and loci. Although the homozygosity mapping approach used in this study may have missed compound heterozygous mutations in the currently known LCA and juvenile RP genes, at least a portion of them is likely to have homozygous mutations in new LCA genes. The homozygous regions identified in these patients may be instrumental in identifying additional new LCA genes.
Homozygosity mapping is a well-known approach for identifying novel disease-causing genes in large to midsized consanguineous families, but it was not clear that it would work so well in very small families and isolated cases. In this study, we show that homozygosity mapping can be used very effectively not only for gene-finding, but also as a mutation screening tool. This result may have implications regarding the choice of which method to use for mutation screening of patients with LCA. LCA mutation chips (Asper Ophthalmics) are relatively cheap, contain all known disease-causing mutations in the known LCA genes, and are currently effective in approximately 60% of patients with LCA. We cannot determine what the efficiency of our homozygosity mapping approach would be in new patients diagnosed with LCA, since most of the samples analyzed in this study were prescreened with the LCA mutation chip. However, considering that 10K SNP arrays are currently cheaper than LCA mutation chips, homozygosity mapping with 10K SNP microarrays may be the best choice for mutation analysis in patients from consanguineous marriages, particularly when they originate from isolated populations that may have private mutations that are not present on the LCA mutation chip. If more than one known LCA gene is located in a homozygous segment, we would propose to prioritize sequencing of the genes based on the size of the homozygous regions.
Our clinical evaluations of the genotyped patients with LCA and juvenile RP reveal three important patterns. First, it may be possible to predict the causal LCA and/or juvenile RP gene from the retinal or other phenotypic aspect of disease. We correctly predicted the involvement of the TULP1 gene based on the disease phenotype, which we believe is specific for TULP1—namely, early-onset nyctalopia with nystagmus; relative preservation of the isopters on kinetic perimetry, despite 20/200 visual acuity; and a perifoveal yellow annular ring. Also, patients with LRAT mutations can be recognized clinically, but overlap significantly with patients who harbor RPE65 mutations.23 Second, heterozygous carriers of recessive retinal dystrophy mutations may develop a subclinical phenotype that may point to the causal gene.27 28 29 We found peculiar, previously unreported yellow subretinal lesions in one of the TULP1 carriers. Much work remains to find an explanation for carrier phenotypes. Third, our work illustrates that LCA and juvenile RP overlap clinically and genetically, as we identified the identical LRAT mutation (c.217_218delAT) in both types of patients. The LCA patient was profoundly visually impaired from birth and remained relatively stable during our 33-year follow-up, whereas the two sibs with juvenile RP and the same LRAT genotype, clearly were born with vision, and presented, not only with visual loss but with nyctalopia, both of which progressed over time. Genetic and environmental factors may modulate the disease phenotype in LRAT patients, causing some to exhibit the LCA phenotype, whereas others develop juvenile RP.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication May 24, 2007; revised July 30, 2007; accepted October 1, 2007.
Disclosure: A.I. den Hollander, None; I. Lopez, None; S. Yzer, None; M.N. Zonneveld, None; I.M. Janssen, None; T. M. Strom, None; J.Y. Hehir-Kwa, None; J.A. Veltman, None; M.L. Arends, None; T. Meitinger, None; M.A. Musarella, None; L.I. van den Born, None; G.A. Fishman, None; I.H. Maumenee, None; K. Rohrschneider, None; F.P.M. Cremers, None; R.K. Koenekoop, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Anneke I. den Hollander, Department of Human Genetics, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands; a.denhollander{at}antrg.umcn.nl.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |